Compare

OPKO Health/$OPK

1D1W1M3M6MYTD1Y5YMAX

About OPKO Health

OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.
Ticker
$OPK
Sector
Health
Primary listing
NASDAQ
Employees
2,275

OPKO Health Metrics

BasicAdvanced
$1.2B
-
-$0.20
1.53
-

What the Analysts think about OPKO Health

Analyst ratings (Buy, Hold, Sell) for OPKO Health stock.
Analyst projections of the future price of OPKO Health stock.

Bulls say / Bears say

Labcorp has agreed to pay $722 million in cash for substantially all of BioReference, with up to $150 million more tied to future 4Kscore sales. If completed, the deal would give OPKO substantial funds to focus on its pharmaceutical and biotech businesses. (OPKO Health)
Continuing-operations revenue rose 16% in the third quarter, while Global Products moved to $6 million of operating income from a loss a year earlier. Growth in Rayaldee, international sales and Lilly royalties supports the case for a stronger core business. (OPKO Health)
OPKO has begun a first-in-human trial of its long-acting acromegaly candidate OPK-8801001, and its BARDA-funded MDX2301 trial has completed enrolment. Positive results could add value to a broad pipeline, although both programmes remain at an early stage. (OPKO Health)
The continuing business remains loss-making: its third-quarter net loss was $35.5 million, while Innovative Biotech’s operating loss widened to $26.8 million as research spending increased. Pipeline investment may therefore keep weighing on results before products reach the market. (OPKO Health)
The Labcorp sale still needs regulatory clearance, and management expects about $125 million of transaction and transition costs, alongside a roughly $40 million fourth-quarter loss from discontinued operations. OPKO has also withdrawn its earlier services and total-cost guidance, leaving near-term results less certain. (The Motley Fool, OPKO Health)
OPKO used $99.1 million of cash in operations during the first nine months of 2026, and its royalty-backed senior notes now total $375 million. The financing brings cash forward but encumbers royalties from mazdutide and adds a sizeable secured debt obligation. (OPKO Health)
Data summarised monthly by Lightyear AI. Last updated on 11 Nov 2026.

OPKO Health Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

OPKO Health Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing OPKO Health

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.